Presbyopia, the age-related loss of near vision, occurs when the eye’s crystalline lens stiffens. A known lens-softening drug, Bistatin, affects too many eye structures to be safe. This research creates a targeted antibody–drug conjugate that delivers Bistatin only to the lens, restoring flexibility and offering a potential non-surgical treatment.